» Articles » PMID: 35272496

Lung-kidney Interactions and Their Role in Chronic Kidney Disease-associated Pulmonary Diseases

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic illnesses rarely present in a vacuum, devoid of other complications, and chronic kidney disease is hardly an exception. Comorbidities associated with chronic kidney disease lead to faster disease progression, expedited dialysis dependency, and a higher mortality rate. Although chronic kidney disease is most commonly accompanied by cardiovascular diseases and diabetes, there is clear cross talk between the lungs and kidneys pH balance, phosphate metabolism, and immune system regulation. Our present understanding of the exact underlying mechanisms that contribute to chronic kidney disease-related pulmonary disease is poor. This review summarizes the current research on kidney-pulmonary interorgan cross talk in the context of chronic kidney disease, highlighting various acute and chronic pulmonary diseases that lead to further complications in patient care. Treatment options for patients presenting with chronic kidney disease and lung disease are explored by assessing activated molecular pathways and the body's compensatory response mechanisms following homeostatic imbalance. Understanding the link between the lungs and kidneys will potentially improve health outcomes for patients and guide healthcare professionals to better understand how and when to treat each of the pulmonary comorbidities that can present with chronic kidney disease.

Citing Articles

Gucy1α1 specifically marks kidney, heart, lung and liver fibroblasts.

Rudman-Melnick V, Vanhoutte D, Stowers K, Sargent M, Adam M, Ma Q Sci Rep. 2024; 14(1):29307.

PMID: 39592775 PMC: 11599588. DOI: 10.1038/s41598-024-80930-0.


Review of Exercise Interventions to Improve Clinical Outcomes in Nondialysis CKD.

Hayden C, Begue G, Gamboa J, Baar K, Roshanravan B Kidney Int Rep. 2024; 9(11):3097-3115.

PMID: 39534200 PMC: 11551061. DOI: 10.1016/j.ekir.2024.07.032.


Accelerated calciprotein crystallization time (T50) is correlated with impaired lung diffusion capacity in systemic sclerosis.

Geroldinger-Simic M, Sohail A, Razazian M, Krennmayr B, Pernsteiner V, Putz T Front Immunol. 2024; 15:1425885.

PMID: 39399492 PMC: 11466802. DOI: 10.3389/fimmu.2024.1425885.


Lung-Kidney Axis in Cystic Fibrosis: Early Urinary Markers of Kidney Injury Correlate with Neutrophil Activation and Worse Lung Function.

Rosner G, Goswami H, Sessions K, Mendyka L, Kerin B, Vlasac I medRxiv. 2024; .

PMID: 39371147 PMC: 11451629. DOI: 10.1101/2023.11.10.23298378.


The Hidden Link between Chronic Kidney Disease and Lung Injury.

Redente E Am J Respir Cell Mol Biol. 2024; 71(6):628-629.

PMID: 39137327 PMC: 11622630. DOI: 10.1165/rcmb.2024-0326ED.


References
1.
Cavalli G, Fallanca F, Dinarello C, Dagna L . Treating pulmonary silicosis by blocking interleukin 1. Am J Respir Crit Care Med. 2015; 191(5):596-8. DOI: 10.1164/rccm.201412-2150LE. View

2.
Shlipak M, Fried L, Crump C, Bleyer A, Manolio T, Tracy R . Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation. 2003; 107(1):87-92. DOI: 10.1161/01.cir.0000042700.48769.59. View

3.
Musgrove J, Wolf M . Regulation and Effects of FGF23 in Chronic Kidney Disease. Annu Rev Physiol. 2019; 82:365-390. DOI: 10.1146/annurev-physiol-021119-034650. View

4.
Su H, Lei C, Zhang C . Interleukin-6 Signaling Pathway and Its Role in Kidney Disease: An Update. Front Immunol. 2017; 8:405. PMC: 5399081. DOI: 10.3389/fimmu.2017.00405. View

5.
Tuder R . Pulmonary vascular remodeling in pulmonary hypertension. Cell Tissue Res. 2016; 367(3):643-649. PMC: 5408737. DOI: 10.1007/s00441-016-2539-y. View